This article by Julie Gallagher appeared in Drug Store News on April 1, 2026
DSN asked several pharmaceutical company executives about the greatest areas of opportunity, how their organizations are positioning to capitalize on them and what changes they believe are necessary to build a more resilient, patient-focused generics ecosystem.
DSN: What is the greatest area of opportunity in the generics space?
Stephen Beckman, CEO, YARAL Pharma Inc.: It’s moving beyond a purely commodity mindset and refocusing on value—specifically the balance of access, quality, reliability and the right price. Generics already make up more than 90% of all prescriptions, but the industry has pushed price competition so far that it has created supply issues and, in some cases, unsustainable economics.
Where I see real opportunity is in complex generics and differentiated delivery platforms that solve real problems for specific patient populations. Instead of trying to be everything to everyone, it’s about focusing on “the right marbles, not the most marbles.”
When you invest in the right products, especially those designed to meet the unique needs of underserved patient populations who are often overlooked in the generics space, you can create a more sustainable model and improve patient outcomes at the same time.